Abstract: An oral composition, particularly a gel, is provided which includes at least 2%, preferably 6% or higher of hydrogen peroxide in a carrier stabilized by a triphenylmethane dye. Particularly useful as the dye are FD&C Blue 1 and FD&C Green 3 at levels ranging from 0.006 to 1 %. Further stability can also be achieved through use of a chelating acid, particularly phosphoric acid.
Type:
Grant
Filed:
June 27, 1997
Date of Patent:
December 8, 1998
Assignee:
Chesebrough-Pond's USA Co., Division of Conopco, Inc.
Inventors:
Stephen Roy Barrow, Jesus Antonio Urbaez
Abstract: A method, composition and kit for effecting hemostasis of a bleeding point and/or dissociating an adherent blood clot at a lesion site on an internal organ, include a composition comprising hydrogen peroxide and surfactant. The composition is applied to the site thereby effecting hemostasis and clot dissociation and clearing the field for endoscopy.
Abstract: This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
Abstract: A method of removal or retardation of growth of hair on the human body by application of phenol, a phenol derivative or a combination of at least two from the group of phenol and phenol derivatives. The element or combination is in the form of a liquid or paste and is applied to the skin and thereafter removed by cleansing. Hair growth is thereafter retarded or eliminated.
Abstract: A lipid emulsion suitable for use as a parenteral or enteral foodstuff, wherein the lipid phase is a mixture of long-chain fatty acids in which 15 to 45% of the total fatty acids are essential fatty acids.
Abstract: An antiinflammatory agent for external use, containing nimesulide as the active ingredient dispersed in the base component and being well absorbable, safe and discoloration-free.
Abstract: Treatment of acne through topical administration is an aspect of the present invention. Specifically, opioids may be applied in any therapeutically acceptable carrier including gels, creams, lotions, and sprays. Therapeutic effects observed with the present invention include decrease in redness, swelling, and inflammation. Treatment of other inflammatory conditions is also disclosed. Treatment of suitable conditions in accordance with the present invention results in significant improvements in healing of those conditions.
Abstract: Compositions and methods are useful for alleviating symptoms of diabetes in mammals. Some of the compositions include a zinc salt and cyclo-Hispro, and optionally contain arachidonic acid. Alternative compositions include a zinc salt, arachidonic acid and L-histidine. The compositions can be administered by oral route according to a daily regimen to result in decreased blood glucose concentrations.
Abstract: A pharmaceutical composition comprising:i) an antifungal agent which is (-)-(2R-cis)-4-?4-?4-?4-??-5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-t riazol-1-ylmethyl)furan-3-yl!methoxy!phenyl!-1-piperazinyl!phenyl!-2,4-dihy dro-2-?(S)-1-ethyl-2(S)-hydroxypropyl!-3H-1,2,4-triazol-3-one;ii) at least one non-ionic surfactant; andiii) a diluent.The composition enables the antifungal compound, which has very low water solubility, to have enhanced bioavailability in mammals, such as humans.
Type:
Grant
Filed:
May 21, 1997
Date of Patent:
November 10, 1998
Assignee:
Schering Corporation
Inventors:
Surendra A. Sangekar, Winston A. Vadino, Ping I. Lee
Abstract: The invention provides novel benzothiophenes of the formula (I): ##STR1## wherein R.sub.1 is N-pyrrolidinyl or N-piperidinyl; R.sub.2 and R.sub.3 are independently hydrogen, --CO--(C.sub.10 -C.sub.22 alkyl), --CO--(C.sub.10 -C.sub.22 branched alkyl), --CO--(C.sub.10 -C.sub.22 alkenyl), --CO--(C.sub.10 -C.sub.22 polyalkenyl), --CO--(C.sub.10 -C.sub.22 alkynyl), or --CO--(CH.sub.2).sub.n COR.sub.4 ; provided R.sub.2 and R.sub.3 are not both dodecanoyl, and one of R.sub.2 or R.sub.3 is not hydrogenR.sub.4 is -3-cholesteryl or --O(CH.sub.2).sub.2 (OR.sub.5)CH.sub.2 OR.sub.6 ;R.sub.5 and R.sub.6 are independently hydrogen, --CO--(C.sub.10 -C.sub.22 alkyl), --CO--(C.sub.10 -C.sub.22 branched alkyl), --CO--(C.sub.10 -C.sub.22 alkenyl), --CO--(C.sub.10 -C.sub.22 polyalkenyl), or --CO--(C.sub.10 -C.sub.22 alkynyl); provided one of R.sub.5 or R.sub.6 is not hydrogen;n is 0-4; and pharmaceutically acceptable salts and solvates thereof.
Type:
Grant
Filed:
October 3, 1997
Date of Patent:
October 27, 1998
Assignee:
Eli Lilly and Company
Inventors:
George Joseph Cullinan, Raymond Francis Kauffman
Abstract: There is disclosed a method for improving the weight gain of swine. The invention also comprises a method of improving the feed conversion efficiency of swine. The improved method comprises administering orally to swine an effective amount of copper citrate and an amount of feed sufficient to produce weight gain in swine.
Abstract: A method for treating treating drug and alcohol addiction comprising administering to a human suffering from such addiction an effective amount of an acetylcholine esterase reactivator.
Type:
Grant
Filed:
February 21, 1997
Date of Patent:
October 20, 1998
Assignee:
Synapse Pharmaceuticals International, Inc.
Abstract: This invention provides methods for the treatment or prevention of cerebral focal ischemia which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B.sub.4 antagonist.
Type:
Grant
Filed:
December 2, 1997
Date of Patent:
October 6, 1998
Assignee:
Eli Lilly and Company
Inventors:
Jerome H. Fleisch, William T. Jackson, Jason S. Sawyer
Abstract: A nutritional product is provided for cancer patients comprising, as per caloric requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L-tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies.
Abstract: A method for the treatment of Meniere's disease comprising the administration of a medicament which modulates the IKs channel of the ear and thereby reducing endolymph production.
Type:
Grant
Filed:
June 24, 1997
Date of Patent:
October 6, 1998
Assignee:
Merck & Company, Inc.
Inventors:
Peter K. S. Siegl, Allan I. Goldberg, Michael R. Goldberg, Paul I. Chang
Abstract: The use of compounds of formula I as topical agents to combat the disorders of the skin, produced by photodamage, which disorders include wrinkling, elastosis and premature aging is described. Compounds of formula I are ##STR1## wherein R is hydrogen, fluorine, or hydroxy, R.sub.2 is hydrogen, lower alkyl or halogen, X is .dbd.CH.sub.2 or when R is hydroxy X is hydrogen or .dbd.CH.sub.2, ##STR2## --CH.sub.2 --CH.sub.2 --, provided that when A is --CH.sub.2 --CH.sub.2 --, R.sub.2 is hydrogen or lower alkyl.
Type:
Grant
Filed:
May 16, 1997
Date of Patent:
September 22, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Graeme Findlay Bryce, Milan Radoje Uskokovic
Abstract: A method for improving disturbed behavior and negative mood in animals suffering from dementia, particularly humans suffering from Alzheimer's type dementia, by administration of dronabinol.
Abstract: Compounds of formula (I): ##STR1## where R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen or alkyl and R.sup.3 is hydrogen, alkyl or various organic groups are effective against osteoporosis at doses at which they also effectively control diabetes.
Abstract: The invention relates to the compounds of formula (I) ##STR1## in which R.sub.I, R.sub.II, X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are as defined in claim 1.
Type:
Grant
Filed:
November 20, 1997
Date of Patent:
August 25, 1998
Assignee:
Sanofi
Inventors:
Alain Badorc, Pierre Despeyroux, Daniele Gully, Paul De Cointet, Daniel Frehel, Jean-Pierre Maffrand
Abstract: This is a new therapy and method used to treat moderate and severe exogenous obesity by combining generic phentermine with an SSRI (selective serotonin reuptake inhibitor) drug in specific doses for a brief or even a long duration, 12 months or more. The preferred drugs for the combination are fluoxetine hydrochloride(Prozac), sertraline (Zoloft), fluvoxamine maleate (Luvox) and trazodone hydrochloride (Desyrel).